Ebastine API

Name	Ebastine
Chinese name	依巴斯汀
Cas Number	90729-43-4
Source	India
Qualifications	/CEP/-/-/-

Ebastine is a new type of anti-allergic drug developed by Spain's Almirall company. It was first marketed in Spain in 1990. It belongs to the second-generation long-acting, potent, fast-acting and selective non-sedative oxypiperidine Antihistamine H1 receptor antagonist, has H1 receptor antagonism. Ebastine is better tolerated than astemizole (assimizole), and the obesity that occurs after asimiazole medication and the cardiotoxicity that occurs when it is used with other antibiotics will not occur. In the treatment of critically ill patients, ebastine (20mg/day) is more effective than asimizole, terfenadine and cetirizine. Ebastine has a protective effect on bronchospasm induced by histamine. Experiments have confirmed that its protective effect is 4.5 times that of terfenadine and 2.9 times that of asimiazole. It does not accumulate after continuous medication. The protective effect of its metabolite Carebestine on bronchospasm induced by histamine is three times that of the original drug. From 2013 to 2018, the market sales of allergy treatment drugs in China increased from 11.128 billion yuan to 21.569 billion yuan, with a compound annual growth rate of 14.15%. The demand for anti-allergic drugs has been on the rise, and the market prospect is huge.

Hot Tags: ebastine api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Escitalopram Oxalate API, Pregabalin API, Canagliflozin API, Linagliptin API, Dimethyl Fumarate API, Salmeterol Xinafoate API

• Previous: Saxagliptin Hydrochloride API
• Next: Gabapentin API